CDSCO Panel Approves Updated Package Insert for Novartis' Ofatumumab Injection Dr. Divya Colin16 March 2025 5:45 PM ISTNew Delhi:The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the proposal...
MS drugs taken while breastfeeding may not affect child development, finds new research Dr. Kamal Kant Kohli14 March 2024 9:00 PM ISTCertain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child...
Ofatumumab subcutaneous injection promising treatment option for refractory pemphigus vulgaris: Study Medha Baranwal4 March 2024 2:00 AM ISTChina: A recent study published in The Journal of Dermatology has suggested ofatumumab to be a promising treatment option for patients with refractory...
CDSCO Panel Approves Novartis Protocol Amendment Proposal For Multiple Sclerosis Drug Ofatumumab Dr. Divya Colin11 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel Grants Novartis Protocol Amendment For Ofatumumab Dr. Divya Colin31 Dec 2023 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Arzerra associated with lower relapse rate in multiple sclerosis patients: ASCLEPIOS trial Medha Baranwal9 Aug 2020 3:00 PM ISTUSA: Ofatumumab lowers relapse rate in patients with multiple sclerosis as compared to teriflunomide, suggests a recent study in the New England...
